Syntekabio, AI Bio Supercomputing Center Completion Commemoration Networking Day

AI drug development company SynthecaBio announced on the 24th that it held the "2nd Networking Day" to commemorate the completion of the newly constructed "AI Bio Supercom (ABS) Center" in the Dungok district of Daejeon.

About 60 attendees from domestic and international medical research institutions, pharmaceutical companies, biotech firms, and related organizations such as the Daejeon Biohealth Industry Division and the Research and Development Special Zone Promotion Foundation participated.

The event began with a welcome speech by SynthecaBio CEO Jo Hye-kyung, followed by congratulatory remarks from Lee Seok-bong, Deputy Mayor for Economy and Science of Daejeon, and Yeo Jae-cheon, Vice Chairman of the Korea New Drug Development Association. The congratulatory message from Kim Woo-yeon, Director of the AI New Drug Development Support Center at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, was read by Deputy Director Jang Woo-soon.

SynthecaBio shared its current business status, future strategies, and vision through the ABS Center. In particular, CEO Jung Jong-sun disclosed plans to modularize major AI drug platforms and services and release them as Software as a Service (SaaS), sharing the business vision utilizing the supercomputing center.

Additionally, the design features and structure of the AI Bio Supercom Center, which applies a natural convection heat dissipation design based on the "African termite mound structure," were introduced, followed by a tour of the supercomputer facilities. Finally, a business networking session was held with employees, pharmaceutical and bio industry representatives, and related organization officials.

Last month, SynthecaBio completed the construction of its own ABS Center in the Dungok district, a hub area of the Daejeon International Science Business Belt. The center covers a site area of 9,917 square meters (approximately 3,000 pyeong), a total floor area of 3,952 square meters (approximately 1,196 pyeong), a building footprint of 1,386 square meters (approximately 420 pyeong), and consists of four above-ground floors. It is the largest facility among AI drug development companies. Including the 3,000 supercomputers previously housed at the Guro Center, it can host up to 10,000 supercomputing devices.

Jung Jong-sun, CEO of SynthecaBio, stated, "Based on the ABS Center, SynthecaBio plans to enhance the technological competitiveness of AI drug platforms such as DeepMatcher and STB CLOUD and provide services tailored to client needs." He added, "Having introduced the ABS Center and revealed our core vision through this Networking Day, we will actively pursue business meetings and sales with potential clients and related organizations to become a leading company in the AI drug platform market."